We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Chaya Brodie is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2005 |
Brodie, Chaya |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Regulation of Glioma Cell Apoptosis in Pkcdelta @ Henry Ford Health System
DESCRIPTION (provided by applicant): PKCdelta is a key enzyme in the regulation of cell apoptosis in various cellular systems. PKCdelta acts as a pro or anti-apoptotic kinase depending on the specific cell type and apoptotic stimulus, however the mechanisms underlying its diverse effects are not understood. In this proposal we seek to understand the molecular mechanisms involved in the regulation of cell apoptosis by PKCdelta focusing on gliomas as a cellular system. Gliomas exhibit deregulated cell apoptosis due to altered apoptotic pathways that favor cell survival. In a recent study we demonstrated that PKCdelta expression is reciprocally correlated with the degree of malignancy in gliomas. Moreover, PKCdelta regulates the apoptosis of these cells in a stimulus-specific manner. The main hypothesis of this proposal is that PKCdelta is a major regulator of glioma cell apoptosis and that the pro and anti-apoptotic effects of PKCdelta in glioma cells are determined by its activation, phosphorylation on distinct tyrosine residues and by its subcellular localization. To test this hypothesis we will employ different apoptotic stimuli and will first examine the role of PKCdelta activity in its pro and anti-apoptotic effects by using a PKCdelta inhibitory peptide, a PKCdelta KD mutant and siRNAs directed against PKCdelta mRNA. Tyrosine phosphorylation of PKCdelta is often induced by apoptotic stimuli. Therefore, the tyrosine phosphorylation of PKCdelta will be studied in response to the various apoptotic stimuli employed in this study. The specific tyrosine residues and the tyrosine kinases involved in their phosphorylation will be identified and their role in the PKCdelta apoptotic effects will be determined. The translocation of PKCdelta in response to the different apoptotic stimuli will be examined using GFP-tagged PKCdelta and the role of PKCdelta tyrosine phosphorylation in the translocation of PKCdelta will be explored using PKCdelta tyrosine mutants. The role of PKCdelta localization in its apoptotic effects will be studied using a PKCdelta mutant in which the NLS was mutated and by employing vectors targeting PKCdelta to the nucleus, ER, cytosol and mitochondria. Finally, the cleavage of PKCdelta and the roles of the cleaved regulatory and catalytic fragments will be studied for their effects on the apoptotic function of PKCdelta. To identify proteins and signaling pathways that mediate the pro and anti-apoptotic effects of PKCdelta the effect of PKCdelta on the levels, activation and phosphorylation of different apoptosis-related proteins and on the activation of signaling pathways associated with cell apoptosis and survival (members of the MAP kinase family and Akt) will be determined. The roles of tyrosine phosphorylation and subcellular localization of PKCdelta in the activation of these proteins will be then evaluated. Another important factor in delineating the function of PKCdelta in glioma cell apoptosis is identifying its binding partners. This will be done using GST-PKCdelta and GST-PKCdelta mutants fusion proteins to identify PKCdelta binding proteins in glioma cells stimulated with different apoptotic stimuli and by screening glioma cDNA libraries using the yeast two hybrid system. The results of this study will enhance our understanding of the factors contributing to the divergent effects of PKCdelta on cell apoptosis and of the role of PKCdelta in the regulation of glioma cell apoptosis. A better understanding of the molecular mechanisms underlying the diverse effects of PKCdelta in gliomas may enable us to predict the tumor response to therapy based on its molecular profile and may lead to novel approaches for altering the sensitivity of gliomas to specific therapeutic agents.
|
0.906 |
2006 — 2008 |
Brodie, Chaya |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
"Regulation of Glioma Cell Apoptosis in Pkcdelta" @ Henry Ford Health System
DESCRIPTION (provided by applicant): PKCdelta is a key enzyme in the regulation of cell apoptosis in various cellular systems. PKCdelta acts as a pro or anti-apoptotic kinase depending on the specific cell type and apoptotic stimulus, however the mechanisms underlying its diverse effects are not understood. In this proposal we seek to understand the molecular mechanisms involved in the regulation of cell apoptosis by PKCdelta focusing on gliomas as a cellular system. Gliomas exhibit deregulated cell apoptosis due to altered apoptotic pathways that favor cell survival. In a recent study we demonstrated that PKCdelta expression is reciprocally correlated with the degree of malignancy in gliomas. Moreover, PKCdelta regulates the apoptosis of these cells in a stimulus-specific manner. The main hypothesis of this proposal is that PKCdelta is a major regulator of glioma cell apoptosis and that the pro and anti-apoptotic effects of PKCdelta in glioma cells are determined by its activation, phosphorylation on distinct tyrosine residues and by its subcellular localization. To test this hypothesis we will employ different apoptotic stimuli and will first examine the role of PKCdelta activity in its pro and anti-apoptotic effects by using a PKCdelta inhibitory peptide, a PKCdelta KD mutant and siRNAs directed against PKCdelta mRNA. Tyrosine phosphorylation of PKCdelta is often induced by apoptotic stimuli. Therefore, the tyrosine phosphorylation of PKCdelta will be studied in response to the various apoptotic stimuli employed in this study. The specific tyrosine residues and the tyrosine kinases involved in their phosphorylation will be identified and their role in the PKCdelta apoptotic effects will be determined. The translocation of PKCdelta in response to the different apoptotic stimuli will be examined using GFP-tagged PKCdelta and the role of PKCdelta tyrosine phosphorylation in the translocation of PKCdelta will be explored using PKCdelta tyrosine mutants. The role of PKCdelta localization in its apoptotic effects will be studied using a PKCdelta mutant in which the NLS was mutated and by employing vectors targeting PKCdelta to the nucleus, ER, cytosol and mitochondria. Finally, the cleavage of PKCdelta and the roles of the cleaved regulatory and catalytic fragments will be studied for their effects on the apoptotic function of PKCdelta. To identify proteins and signaling pathways that mediate the pro and anti-apoptotic effects of PKCdelta the effect of PKCdelta on the levels, activation and phosphorylation of different apoptosis-related proteins and on the activation of signaling pathways associated with cell apoptosis and survival (members of the MAP kinase family and Akt) will be determined. The roles of tyrosine phosphorylation and subcellular localization of PKCdelta in the activation of these proteins will be then evaluated. Another important factor in delineating the function of PKCdelta in glioma cell apoptosis is identifying its binding partners. This will be done using GST-PKCdelta and GST-PKCdelta mutants fusion proteins to identify PKCdelta binding proteins in glioma cells stimulated with different apoptotic stimuli and by screening glioma cDNA libraries using the yeast two hybrid system. The results of this study will enhance our understanding of the factors contributing to the divergent effects of PKCdelta on cell apoptosis and of the role of PKCdelta in the regulation of glioma cell apoptosis. A better understanding of the molecular mechanisms underlying the diverse effects of PKCdelta in gliomas may enable us to predict the tumor response to therapy based on its molecular profile and may lead to novel approaches for altering the sensitivity of gliomas to specific therapeutic agents.
|
0.906 |
2009 — 2010 |
Brodie, Chaya |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Regulation of Glioma Cell Migration by Rasgrp3 @ Henry Ford Health System
Gliomas, the most frequent primary brain tumors, exhibit very poor prognosis which is largely due to their highly infiltrative nature. Genetic and biochemical studies have demonstrated that gliomagenesis involves stepwise accumulation of genetic alterations of signal transduction pathways and cell cycle related proteins. Indeed, signaling pathways such as Ras/Erk/AKT and pathways coupled to diacylglycerol (DAG) production are highly active in glioma cells. RasGRP3 is a guanine nucleotide exchange factor (GEF) that activates small GTPases including Ras and Rap1. RasGRP3 is activated by DAG which is generated by phospholipase Cg downstream of activated growth factors receptors in glioma cells. The activation of RasGRP3 is controlled by membrane recruitment through its DAG binding C1 domain. Our preliminary results demonstrate that RasGRP3 is expressed in gliomas and regulates glioma cell migration and invasion and the activation of Ras, Rap1 and the AKT and Erk1/2 pathways. In addition, using a pull-down assay, we recently identified Arp3 as a novel interacting protein of RasGRP3 in glioma cells. Since Arp3 regulates cell migration, we hypothesized that RasGRP3 plays a major role in glioma cell migration via its interaction with this protein. The main objective of this study is therefore to delineate the mechanisms involved in RasGRP3 effects on glioma cell migration in vitro and in vivo focusing on its interaction with Arp3. Specifically, we will further characterize the interaction of the endogenous and overexpressed RasGRP3 and Arp3 using co-immunoprecipitation, immunofluorescence staining for co-localization and FRET assays for the determination of a direct interaction. Since Arp3 plays a major role in actin polymerization which leads to cell spreading and cell migration, we will determine the role of RasGRP3 and its interaction with Arp3 in these processes. We will also examine the possibility that Arp3 acts as an anchoring/scaffold protein for RasGRP3 during its translocation. Finally, we will examine the role of RasGRP3 and Arp3 in glioma cell migration in vivo using xenografts derived from U87 cells overexpressing RasGRP3 and CD133+ glioma stem cells in which RasGRP3 is silenced. The results of these studies will delineate the role of RasGRP3 in glioma cell migration focusing on its interaction with Arp3 and may provide the basis for the development of novel therapeutic approaches for the treatment of malignant glioma using RasGRP3 as a molecular target.
|
0.906 |